Fig. 5

ZNF468 promotes the growth, migration and cisplatin resistance of BC cells through up-regulation of TFAM. A Immunoblotting assay was performed to check the protein expression of TFAM in Ctrl, ZNF468 and ZNF468+siTFAM MCF-7 cells. B CCK-8 was conducted to detect the viability of MCF-7 cells as described in A. **p < 0.01. C MCF-7 cells described in A were treated with vehicle and different concentrations of cisplatin (1, 5, 10 and 20 μM) for 48 h. Cell viability was detected by CCK-8 assay. *p < 0.05. **p < 0.01. D Immunoblotting assay was performed to check the protein expression of TFAM in siCtrl, siZNF468#1 and siZNF468#1+TFAM MDA-MB-231 cells. E CCK-8 was conducted to detect the viability of MDA-MB-231 cells as described in D. *p < 0.05. **p < 0.01. F MDA-MB-231 cells as described in D were treated with vehicle and different concentrations of cisplatin (1, 5, 10 and 20 μM) for 48 h. Cell viability was detected by CCK-8 assay. *p < 0.05. G, H Cell migration was checked by Transwell asasy for Ctrl, ZNF468 and ZNF468+siTFAM MCF-7 cells. *p < 0.05. **p < 0.01. I, J Cell migration was checked by Transwell asasy for siCtrl, siZNF468#1 and siZNF468#1+TFAM MDA-MB-231 cells. **p < 0.01. For immunoblotting assays, the blots were cut prior to hybridisation with antibodies